Effect of mesenchymal stem cells on the balance of Th17/Treg and its relationship with IBD

doi:10.3877/cma.j.issn.2095-1221.2018.06.009

Abstract

Abstract:

T helper cell 17 (Th17)/regulatory T(Treg) cell imbalance is an important factor in the pathogenesis of inflammatory bowel disease (IBD). Correcting Th17/Treg imbalance can slow or inhibit the development of IBD and become a target for the treatment of IBD. Mesenchymal stem cells (MSCs) have anti-inflammatory and immunoregulatory functions and can regulate adaptive and innate immunity through cell contacts and secretion of soluble factors and exosomes. MSCs alleviate IBD by correcting Th17/Treg imbalance. This paper reviews the regulation of Th17/Treg balance by MSCs and its relationship with IBD.

Key words: Inflammatory bowel disease, Mesenchymal stem cells, T helper cell 17, Regulatory T cells

zhengwei Fu, Lixia Wang, Haiyan Ge. Effect of mesenchymal stem cells on the balance of Th17/Treg and its relationship with IBD[J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2018, 08(06): 373-378.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxbygxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-1221.2018.06.009

https://zhxbygxbzz.cma-cmc.com.cn/EN/Y2018/V08/I06/373

References 59

1	Griffin MD, Elliman SJ, Cahill E, et al. Concise review: adult mesenchymal stromal cell therapy for inflammatory diseases: how well are we joining the dots?[J]. Stem Cells, 2013, 31(10):2033-2041.
2	Danese S. New therapies for inflammatory bowel disease: from the bench to the bedside[J]. Gut, 2012, 61(6):918-932.
3	Saldanha-Araujo F, Ferreira FI, Palma PV, et al. Mesenchymal stromal cells up-regulate CD39 and increase adenosine production to suppress activated T-lymphocytes[J]. Stem Cell Res, 2011, 7(1):66-74.
4	Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo[J]. Exp Hematol, 2002, 30(1):42-48.
5	Takebe Y, Tatehara S, Fukushima TA, et al. Cryopreservation method for the effective collection of dental pulp stem cells[J]. Tissue Eng Part C Methods, 2017, 23(5):251-261.
6	Bellavia M, Altomare R, Cacciabaudo F, et al. Towards an ideal source of mesenchymal stem cell isolation for possible therapeutic application in regenerative medicine[J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2014, 158(3):356-360.
7	Stoltz JF, De Isla N, Li YP, et al. Stem cells and regenerative medicine: myth or reality of the 21th century[J]. Stem Cells Int, 2015 (2015):1-19.
8	Ye JS, Su XS, Stoltz JF, et al. Signalling pathways involved in the process of mesenchymal stem cells differentiating into hepatocytes[J]. Cell Prolif, 2015, 48(2):157-165.
9	Reppel L, Margossian T, Yaghi L, et al. Hypoxic culture conditions for mesenchymal stromal/stem cells from wharton's jelly: a critical parameter to consider in a therapeutic context[J]. Curr Stem Cell Res Ther, 2014, 9(4):306-318.
10	Horwitz EM, Le Blanc K, Dominici M, et al. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement [J]. Cytotherapy, 2005, 7(5):393-395.
11	Kavanagh H, Mahon BP. Allogeneic mesenchymal stem cells prevent allergic airway inflammation by inducing murine regulatory T cells[J]. Allergy, 2011, 66(4):523-531.
12	Caplan AI. Why are MSCs therapeutic? New data: new insight[J]. J Pathol, 2009, 217(2):318-324.
13	Sun YQ, Deng MX, He J, et al. Human pluripotent stem cell-derived mesenchymal stem cells prevent allergic airway inflammation in mice [J]. Stem Cells, 2012, 30(12):2692-2699.
14	Han KH, RO H, Hong JH, et al. Immunosuppressive mechanisms of embryonic stem cells and mesenchymal stem cells in alloimmune response[J]. Transpl Immunol, 2011, 25(1):7-15.
15	Krampera M, Glennie S, Dyson J, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide[J]. Blood, 2003, 101(9):3722-3729.
16	English K, Ryan JM, Tobin L, et al. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4⁺ CD25(High) forkhead box P3⁺ regulatory T cells[J]. Clin Exp Immunol, 2009, 156(1):149-160.
17	Raicevic G, Najar M, Najimi M, et al. Influence of inflammation on the immunological profile of adult-derived human liver mesenchymal stromal cells and stellate cells[J]. Cytotherapy, 2015, 17(2):174-185.
18	Delarosa O, Lombardo E, Beraza AA, et al. Requirement of IFN-gamma-mediated indoleamine 2,3-dioxygenase expression in the modulation of lymphocyte proliferation by human adipose-derived stem cells[J]. Tissue Eng Part A, 2009, 15(10):2795-2806.
19	Sanchez-AI, Alvarez-LI, Diez-CM, et al. Uptake and delivery of antigens by mesenchymal stromal cells[J]. Cytotherapy, 2013, 15(6):673-678.
20	Ren G, Zhao X, Zhang L, et al. Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression[J]. J Immunol, 2010, 184(5):2321-2328.
21	Hemeda H, Jakob M, Ludwig AK, et al. Interferon-gamma and tumor necrosis factor-alpha differentially affect cytokine expression and migration properties of mesenchymal stem cells[J]. Stem Cells Dev, 2010, 19(5):693-706.
22	Maby-El Hajjami H, Amé-Thomas P, Pangault C, et al. Functional alteration of the lymphoma stromal cell niche by the cytokine context: role of indoleamine-2,3 dioxygenase[J]. Cancer Res, 2009, 69(7):3228-3237.
23	Opitz CA, Litzenburger UM, Lutz C, et al. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R[J]. Stem Cells, 2009, 27(4):909-919.
24	Németh K, Leelahavanichkul A, Yuen PS, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production [J]. Nat Med, 2009, 15(1):42-49.
25	Wang Y, Chen XD, Cao W, et al. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications[J]. Nat Immunol, 2014, 15(11):1009-1016.
26	Manuela B, Alessandra F, Rosa L, et al. The immunosuppressive effect of mesenchymal stromal cells on B lymphocytes is mediated by membrane vesicles[J]. Cell Transplant, 2013, 22(2):369-379.
27	Mokarizadeh A, Delirezh N, Morshedi A, et al. Microvesicles derived from mesenchymal stem cells: potent organelles for induction of tolerogenic signaling[J]. Immunol Lett, 2012, 147(1/2):47-54.
28	Yang J, Liu XX, Fan H, et al. Extracellular vesicles derived from bone marrow mesenchymal stem cells protect against experimental colitis via attenuating colon inflammation,oxidative stress and apoptosis[J]. PLoS One, 2015, 10(10):e0140551.
29	Hashemian SJ, Kouhnavard M, Nasli-Esfahani E. Mesenchymal stem cells: rising concerns over their application in treatment of type one diabetes mellitus[J]. J Diabetes Res, 2015 (2015):675103.
30	Tatara R, Ozaki K, Kikuchi Y, et al. Mesenchymal stromal cells inhibit Th17 but not regulatory T-cell differentiation[J]. Cytotherapy, 2011, 13(6):686-694.
31	Ghannam S, Pène J, Moquet-Torcy G, et al. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype[J]. J Immunol, 2010, 185(1):302-312.
32	Oukka M. Th17 cells in immunity and autoimmunity[J]. Ann Rheum Dis, 2008, 67(3):26-29.
33	Manel N, Unutmaz D, Littman DR. The differentiation of human T(H)- 17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat[J]. Nat Immunol, 2008, 9(6):641-649.
34	Quintana FJ, Basso AS, Iglesias AH, et al. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor[J]. Nature, 2008, 453(7191):65-71.
35	Liu C, Qian W, Qian Y, et al. Act1, a U-box E3 ubiquitin ligase for IL- 17 signaling [J]. Sci Signal, 2009, 2(92):ra63.
36	Andolfi G, Fousteri G, Rossetti M, et al. Enforced IL-10 expression confers type 1 regulatory T cell (Tr1) phenotype and function to human CD4(+) T cells[J]. Mol Ther, 2012, 20(9):1778-1790.
37	Schmidt A, Oberle N, Krammer PH. Molecular mechanisms of treg- mediated T cell suppression[J]. Front Immunol, 2012, 3(21):51.
38	Hongo D, Tang XB, Dutt S, et al. Interactions between NKT cells and Tregs are required for tolerance to combined bone marrow and organ transplants[J]. Blood, 2012, 119(6):1581-1589.
39	Gondek DC, Devries V, Nowak EC, et al. Transplantation survival is maintained by granzyme B+ regulatory cells and adaptive regulatory T cells[J]. J Immunol, 2008, 181(7):4752-4760.
40	Zhu XM, Shi YZ, Cheng M, et al. Serum IL-6, IL-23 profile and Treg/ Th17 peripheral cell populations in pediatric patients with inflammatory bowel disease[J]. Pharmazie, 2017, 72(5):283-287.
41	Ju JH, Heo YJ, Cho ML, et al. Modulation of STAT-3 in rheumatoid synovial T cells suppresses Th17 differentiation and increases the proportion of Treg cells[J]. Arthritis Rheum, 2012, 64(11):3543-3552.
42	Fonseca-Camarillo G, Yamamoto-Furusho JK. Immunoregulatory pathways involved in inflammatory bowel disease[J]. Inflamm Bowel Dis, 2015, 21(9):2188-2193.
43	Li J, Glover SC. Innate lymphoid cells in inflammatory bowel disease [J]. Arch Immunol Ther Exp (Warsz), 2018, 66(6):415-421.
44	Li J, Ueno A, Gasia MF, et al. Profiles of lamina propria T helper cell subsets discriminate between ulcerative colitis and crohn's disease[J]. Inflamm Bowel Dis, 2016, 22(8):1779-1792.
45	Monteleone I, Sarra M, Pallone F, et al. Th17-Related cytokines in inflammatory bowel diseases: friends or Foes?[J]. Curr Mol Med, 2012, 12(5):592-597.
46	Salas A, Panes JI. Regulatory T cells for treatment of Crohn's disease [J]. Nat Rev Gastroenterol Hepatol, 2015, 12(6):315-316.
47	Ogino H, Nakamura K, Ihara E, et al. CD4(+)CD25(+) regulatory T cells suppress Th17-Responses in an experimental colitis model[J]. Dig Dis Sci, 2011, 56(2):376-386.
48	Menning A, Loddenkemper C, Westendorf AM, et al. Retinoic acid-induced gut tropism improves the protective capacity of Treg in acute but not in chronic gut inflammation[J]. Eur J Immunol, 2010, 40(9):2539-2548.
49	Jiang XP, Huang XL, Yang ZP, et al. Iguratimod ameliorates inflammatory responses by modulating the Th17/Treg paradigm in dextran sulphate sodium-induced murine colitis[J]. Mol Immunol, 2018, 93(1):9-19.
50	Lim SM, Jeong JJ, Jang SE, et al. A mixture of the probiotic strains Bifidobacterium longum CH57 and Lactobacillus brevis CH23 ameliorates colitis in mice by inhibiting macrophage activation and restoring the Th17/Treg balance[J]. J Funct Foods, 2016, 27: 295-309.
51	Ma Y, Wang Z, Zhang A, et al. Human placenta-derived mesenchymal stem cells ameliorate GVHD by modulating Th17/Tr1 balance via expression of PD-L2[J]. Life Sci, 2018, 214(1):98-105.
52	Kong QF, Sun B, Bai SS, et al. Administration of bone marrow stromal cells ameliorates experimental autoimmune myasthenia gravis by altering the balance of Th1/Th2/Th17/Treg cell subsets through the secretion of TGF-beta[J]. J Neuroimmunol, 2009, 207(1-2):83-91.
53	Cheng Q, Zhang Z, Zhang S, et al. Human umbilical cord mesenchymal stem cells protect against ischemic brain injury in mouse by regulating peripheral immunoinflammation[J]. Brain Res, 2015, 1594(1):293-304.
54	Huang Y, Chen Z. Inflammatory bowel disease related innate immunity and adaptive immunity[J]. Am J Transl Res, 2016, 8(6):2490-2497.
55	刘星星，范恒，唐庆, 等. 过表达CXCR4的间充质干细胞缓解实验性结肠炎[J]. 世界华人消化杂志, 2016 (8):1233-1240.
56	Fu ZW, Zhang ZY, Ge HY. Mesenteric injection of adipose-derived mesenchymal stem cells relieves experimentally-induced colitis in rats by regulating Th17/Treg cell balance[J]. Am J Transl Res, 2018, 10(1):54-66.
57	González MA, Gonzalez-Rey E, Rico L, et al. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses[J]. Gastroenterology, 2009, 136(3):978-989.
58	Bandzar S, Gupta S, Platt MO. Crohn's disease: A review of treatment options and current research [J]. Cell Immunol, 2013, 286(1/2):45-52.
59	Akiyama K, Chen C, Wang D, et al. Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis [J]. Cell Stem Cell, 2012, 10(5):544-555.

[1]	Yangwenxiang Wei, Haoran Huang, Yuhao Liu, Zhenqiu Chen, Haibin Wang, Chi Zhou. Outlooks and challenges in cell therapy of osteonecrosis of femoral head [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(05): 694-700.
[2]	Zhuoyi Fu, Shengcheng Tang, Qiaomei Bu, Gaobing Xu, Anping Wu, Wei Cai, Ming Yang, Haitao Tan. Research progress of magnesium in treatment of osteoarthritis [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(03): 354-362.
[3]	Yingjun Tang, Huajuan Li, Saini Wang, Wang Xu, Feng Liu, Xi Li, Xinbao Hao, Huaping Huang. Effect and mechanism of human umbilical cord mesenchymal stem cells (HU-MSCs) transplantation on emphysema mice [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(04): 476-480.
[4]	nian Li, Jianjun Zhao, Jianyong Zhang, Ruizhen Zhao. Effect of human amniotic mesenchymal stem cell regulating MAPK signaling pathway of aquaporin 1 in acute lung injury [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(02): 156-163.
[5]	Hongmin Wang, Yunbo Xie, Yanhu Wang, Fusheng Wang. The advance of clinical research in mesenchymal stem cell treatment for COVID-19 [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(04): 247-256.
[6]	Wenhui Liu, Tao Wu, Xi Zhang. Advances in mesenchymal stem cells combined with thrombopoietin receptor agonists in platelet recovery after allogeneic hematopoietic stem cell transplantation [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(04): 242-246.
[7]	Huiling Long, Mi Lin, Ting Shao. Research progress and application of three-dimensional spherical mesenchymal stem cell culture technology [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(04): 229-234.
[8]	Ye Li, Jie He, Jinxiu Hu, Jinxiang Wang, Chuan Tian, Hang Pan, Mengdie Chen, Xiaojuan Zhao, Li Ye, Min Zhang, Xinghua Pan. Highly active mesenchymal stem cells interfere with ovarian aging in macaques [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(04): 210-219.
[9]	Fuhao Qin, Zheng Zheng, Bin Jiang. Research progress of mesenchymal stem cells in the treatment of perianal fifistulizing Crohn's disease [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(03): 172-177.
[10]	Jiuli Yuan, Dan Liu, Linli Li, Jinyu Liu. Basic research and clinical application of hair follicle-derived mesenchymal stem cells [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(03): 189-192.
[11]	Yanqi Song, Xuejing Ren, Wenjuan Wang, Qiuxia Han, Yue Xu, Kaiting Zhuang, Tuo Xiao, Guangyan Cai. Effect of mesenchymal stem cells on ferroptosis in cisplatin-induced acute kidney injury of mice [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2023, 12(04): 187-193.
[12]	Yunzhao Yang, Cheng Zhou, Meihan Shi, Jing Zhao, Xueyuan Bai. Therapeutic effect of human amniotic fluid-derived mesenchymal stem cells on membranous nephropathy in rats [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2023, 12(04): 181-186.
[13]	Fengshang Zhu, Ling She, Yongnian Ding, Changqing Yang. Maintaining vigilance in the differential diagnosis of inflammatory bowel disease and rare bowel disorders [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(05): 273-276.
[14]	Jiali Yu, Xueliang Jiang. Application progress of biological agents from the perspective of therapeutic strategy transformation of inflammatory bowel disease [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(03): 129-134.
[15]	Wensong Ge. Dual targeted therapy for the management of inflammatory bowel disease [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(02): 65-67.

Please choose a citation manager

Content to export